Latest Breaking News On - Philipa serlin - Page 1 : vimarsana.com

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...

BioLineRx : Form 20-F/A (Amendment No. 1 -March 28, 2024 at 05:36 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A ...

BioLineRx : Report of Periodic or Interim Report -March 26, 2024 at 08:26 am EDT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...

BioLineRx : Annual Report on Form 20-F FOR 2023 -March 26, 2024 at 08:40 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ...

BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates -March 26, 2024 at 07:36 am EDT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...

BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan -December 31, 2023 at 03:01 am EST

As filed with the Securities and Exchange Commission on December 29, 2023. Registration No. 333- UNITED STATES ...

Form 6-K BioLineRx Ltd. For: Dec 21

Form 6-K BioLineRx Ltd. For: Oct 12